Purified cannabinoids biotech company GW Pharmaceuticals reports quarterly numbers.
It surprised Numis with positive Phase 3 headline results for Epidiolex for the treatment of Dravet back in March and Lennox-Gastaut Syndromes in June, as it expected both these trials to fail.
“We now await further data from the trials, particularly around the drug-drug interactions with Clobazam and details of GW’s subsequent interactions with the US FDA [Food & Drug Administration] that are expected to inform the ongoing Phase 3 Dravet syndrome study,” the broker said.
“The second Phase 3 trial in Lennox-Gastaut is expected to report in Q3, and we await updates from several of GW’s competitors in the orphan epilepsy space in the coming weeks with Zogenix and SAGE also reporting on the 9th August,” it added.
Significant announcements expected
Interims: GW Pharmaceuticals PLC (LON:GWP), Legal & General Group PLC (LON:LGEN), Quarto Group Inc (LON:QRT), Regus PLC (LON:RGU), SIG PLC (LON:SHI), Standard Life PLC (LON:SL.), Worldpay Group PLC (LON:WPG).